

Biodistribution of ^{89}Zr -trastuzumab and PET Imaging of With Metastatic Breast Cancer

Clinical Pharmacology and Therapeutics

87, 586-592

DOI: [10.1038/clpt.2010.12](https://doi.org/10.1038/clpt.2010.12)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Molecular imaging of HER2-positive breast cancer: a step toward an individualized "image and treat"™ strategy. <i>Current Opinion in Oncology</i> , 2010, 22, 559-566.	1.1	95
3	Immuno-Positron Emission Tomography: Shedding Light on Clinical Antibody Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 375-385.	0.7	93
4	Targeting HER2. <i>MAbs</i> , 2010, 2, 550-564.	2.6	50
5	The challenges of integrating molecular imaging into the optimization of cancer therapy. <i>Integrative Biology (United Kingdom)</i> , 2011, 3, 603.	0.6	13
6	New imaging paradigms in drug development: the PET imaging approach. <i>Drug Discovery Today: Technologies</i> , 2011, 8, e63-e69.	4.0	5
7	⁸⁹ Zr-labeled compounds for PET imaging guided personalized therapy. <i>Drug Discovery Today: Technologies</i> , 2011, 8, e53-e61.	4.0	33
8	Opportunities and pitfalls of cancer imaging in clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 517-527.	12.5	31
9	In vivo biodistribution and accumulation of ⁸⁹ Zr in mice. <i>Nuclear Medicine and Biology</i> , 2011, 38, 675-681.	0.3	221
10	Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on ¹¹¹ In- and ¹²⁵ I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody. <i>Nuclear Medicine and Biology</i> , 2011, 38, 1093-1102.	0.3	28
11	The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86. <i>Future Medicinal Chemistry</i> , 2011, 3, 599-621.	1.1	41
12	The Next Generation of Positron Emission Tomography Radiopharmaceuticals in Oncology. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 265-282.	2.5	93
13	Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions. <i>Molecular Imaging</i> , 2011, 10, 7290.2010.00047.	0.7	44
14	Emerging Role of ImmunPET in Receptor Targeted Cancer Therapy. <i>Current Drug Delivery</i> , 2011, 8, 70-78.	0.8	12
15	A comparison of ¹¹¹ In- or ⁶⁴ Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. <i>EJNMMI Research</i> , 2011, 1, 15.	1.1	33
16	Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. <i>EJNMMI Research</i> , 2011, 1, 31.	1.1	78
17	MicroPET Imaging of Integrin $\alpha_3\beta_3$ Expressing Tumors Using ⁸⁹ Zr-RGD Peptides. <i>Molecular Imaging and Biology</i> , 2011, 13, 1224-1233.	1.3	50
18	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 531-539.	3.3	46
19	PET imaging of HER-2-positive tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1961-1963.	3.3	0

#	ARTICLE	IF	CITATIONS
20	Implementation of ⁸⁹ Zr production and in vivo imaging of B-cells in mice with ⁸⁹ Zr-labeled anti-B-cell antibodies by small animal PET/CT. Applied Radiation and Isotopes, 2011, 69, 852-857.	0.7	35
21	Multimodality and nanoparticles in medical imaging. Dalton Transactions, 2011, 40, 6087.	1.6	82
22	Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting Antibodies. Journal of Nuclear Medicine, 2011, 52, 1778-1785.	2.8	186
23	PET with the ⁸⁹ Zr-Labeled Transforming Growth Factor- β Antibody Fresolimumab in Tumor Models. Journal of Nuclear Medicine, 2011, 52, 2001-2008.	2.8	51
24	Toward Molecular Imaging-Driven Drug Development in Oncology. Cancer Discovery, 2011, 1, 25-28.	7.7	21
25	¹²⁴ I-huA33 Antibody PET of Colorectal Cancer. Journal of Nuclear Medicine, 2011, 52, 1173-1180.	2.8	85
26	Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment. Clinical Cancer Research, 2011, 17, 1509-1520.	3.2	34
27	<i>In Vitro</i> Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells. Nucleic Acid Therapeutics, 2011, 21, 173-178.	2.0	83
28	Immuno-PET of Cancer: A Revival of Antibody Imaging. Journal of Nuclear Medicine, 2011, 52, 1171-1172.	2.8	44
29	HER2-Positive Tumors Imaged Within 1 Hour Using a Site-Specifically ¹¹ C-Labeled Sel-Tagged Affibody Molecule. Journal of Nuclear Medicine, 2012, 53, 1446-1453.	2.8	29
30	PET and MRI of Metastatic Peritoneal and Pulmonary Colorectal Cancer in Mice with Human Epidermal Growth Factor Receptor 1-Targeted ⁸⁹ Zr-Labeled Panitumumab. Journal of Nuclear Medicine, 2012, 53, 113-120.	2.8	73
31	Advances in Immuno-Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology. Journal of Clinical Oncology, 2012, 30, 3884-3892.	0.8	176
32	Zirconium-89-Trastuzumab Positron Emission Tomography As a Tool to Solve a Clinical Dilemma in a Patient With Breast Cancer. Journal of Clinical Oncology, 2012, 30, e74-e75.	0.8	32
33	Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model. Journal of Nuclear Medicine, 2012, 53, 629-637.	2.8	34
34	Multifunctional Ligands in Medicinal Inorganic Chemistry- Current Trends and Future Directions. Current Topics in Medicinal Chemistry, 2012, 12, 122-144.	1.0	23
36	Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy. Molecular Cancer Therapeutics, 2012, 11, 1017-1025.	1.9	111
37	⁸⁹ Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors. Pharmaceuticals, 2012, 5, 79-93.	1.7	50
38	Recent Advances in Optical Cancer Imaging of EGF Receptors. Current Medicinal Chemistry, 2012, 19, 4759-4766.	1.2	9

#	ARTICLE	IF	CITATIONS
39	New PET imaging agents in the management of solid cancers. <i>Current Opinion in Oncology</i> , 2012, 24, 748-755.	1.1	9
40	Targeted Nuclear Imaging of Breast Cancer: Status of Radiotracer Development and Clinical Applications. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 105-112.	0.7	12
41	Lapatinib and 17AAG Reduce ⁸⁹ Zr-Trastuzumab-F(ab ϵ) ₂ Uptake in SKBR3 Tumor Xenografts. <i>Molecular Pharmaceutics</i> , 2012, 9, 2995-3002.	2.3	40
42	Development and experimental medicine applications of PET in oncology: a historical perspective. <i>Lancet Oncology</i> , The, 2012, 13, e116-e125.	5.1	34
43	Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular Imaging. <i>AAPS Journal</i> , 2012, 14, 389-399.	2.2	46
44	Positron Emission Tomography of ⁶⁴ Cu-DOTA-Rituximab in a Transgenic Mouse Model Expressing Human CD20 for Clinical Translation to Image NHL. <i>Molecular Imaging and Biology</i> , 2012, 14, 608-616.	1.3	30
45	Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. <i>Immunobiology</i> , 2012, 217, 1266-1272.	0.8	38
46	Is there still a role for SPECTâ€“CT in oncology in the PETâ€“CT era?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 712-720.	12.5	135
47	Multimodality Imaging of Breast Cancer Experimental Lung Metastasis with Bioluminescence and a Monoclonal Antibody Dual-Labeled with ⁸⁹ Zr and IRDye 800CW. <i>Molecular Pharmaceutics</i> , 2012, 9, 2339-2349.	2.3	63
48	Development of a Novel Long-Lived ImmunoPET Tracer for Monitoring Lymphoma Therapy in a Humanized Transgenic Mouse Model. <i>Bioconjugate Chemistry</i> , 2012, 23, 1221-1229.	1.8	36
49	Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions. <i>Radiochimica Acta</i> , 2012, 100, 653-667.	0.5	59
50	Recent trends in antibody-based oncologic imaging. <i>Cancer Letters</i> , 2012, 315, 97-111.	3.2	115
51	Personalized Nanomedicine. <i>Clinical Cancer Research</i> , 2012, 18, 4889-4894.	3.2	166
52	Liposome imaging agents in personalized medicine. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1417-1435.	6.6	146
53	PET Tracers for Clinical Imaging of Breast Cancer. <i>Journal of Oncology</i> , 2012, 2012, 1-9.	0.6	23
54	How Does the Patient Benefit from Clinical PET?. <i>Theranostics</i> , 2012, 2, 427-436.	4.6	12
55	Antibody therapy of cancer. <i>Nature Reviews Cancer</i> , 2012, 12, 278-287.	12.8	1,861
56	PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. <i>Tumor Biology</i> , 2012, 33, 607-615.	0.8	81

#	ARTICLE	IF	CITATIONS
57	Impact of expression system on the function of the C6.5 diabody PET radiotracer. <i>Tumor Biology</i> , 2012, 33, 617-627.	0.8	6
58	The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 119-124.	0.3	0
59	Public-private partnerships in translational medicine: Concepts and practical examples. <i>Journal of Controlled Release</i> , 2012, 161, 416-421.	4.8	15
60	Whither the PET Scan? The Role of PET Imaging in the Staging and Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2012, 14, 20-26.	1.8	3
61	Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 138-148.	3.3	75
62	Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. <i>Pharmaceutical Research</i> , 2012, 29, 770-781.	1.7	182
63	Overview of PET Tracers for Brain Tumor Imaging. <i>PET Clinics</i> , 2013, 8, 129-146.	1.5	23
64	89Zr-Labeled Paramagnetic Octreotide-Liposomes for PET-MR Imaging of Cancer. <i>Pharmaceutical Research</i> , 2013, 30, 878-888.	1.7	81
65	89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges. <i>Molecules</i> , 2013, 18, 6469-6490.	1.7	92
66	Antibody-Drug Conjugate Target Selection: Critical Factors. <i>Methods in Molecular Biology</i> , 2013, 1045, 29-40.	0.4	43
67	Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions. <i>Cancer Letters</i> , 2013, 341, 132-138.	3.2	21
68	PET/CT and breast cancer subtypes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1301-1303.	3.3	5
69	Quantitative imaging of disease signatures through radioactive decay signal conversion. <i>Nature Medicine</i> , 2013, 19, 1345-1350.	15.2	138
70	CNS Metastases in Breast Cancer: Old Challenge, New Frontiers. <i>Clinical Cancer Research</i> , 2013, 19, 6404-6418.	3.2	162
71	Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 101-110.	1.1	25
72	Mapping biological behaviors by application of longer-lived positron emitting radionuclides. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1098-1111.	6.6	39
73	Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments. <i>Nuclear Medicine and Biology</i> , 2013, 40, 630-637.	0.3	22
74	PET imaging with 89Zr: From radiochemistry to the clinic. <i>Nuclear Medicine and Biology</i> , 2013, 40, 3-14.	0.3	338

#	ARTICLE	IF	CITATIONS
75	Radiometals for Combined Imaging and Therapy. <i>Chemical Reviews</i> , 2013, 113, 858-883.	23.0	337
76	Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 1-12.	1.1	25
78	Small Targeted Cytotoxics: Current State and Promises from DNA-Encoded Chemical Libraries. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 1384-1402.	7.2	130
79	Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood-brain barrier. <i>Cancer Treatment Reviews</i> , 2013, 39, 261-269.	3.4	73
80	Radiosynthesis, biodistribution and imaging of [¹¹ C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model. <i>Nuclear Medicine and Biology</i> , 2013, 40, 221-226.	0.3	14
81	Synthesis, Preclinical Validation, Dosimetry, and Toxicity of ⁶⁸ Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 776-784.	2.8	173
82	Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 359-373.	1.1	24
83	Value of ¹¹ C-methionine PET in imaging brain tumours and metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 615-635.	3.3	245
84	Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with ¹⁸ F-FDG and ⁸⁹ Zr-Trastuzumab PET. <i>Journal of Nuclear Medicine</i> , 2013, 54, 936-943.	2.8	85
85	Drug-conjugated antibodies for the treatment of cancer. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 248-262.	1.1	126
86	Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 331-346.	1.1	18
87	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 935-946.	3.4	308
88	Molecular Imaging Probes for Diagnosis and Therapy Evaluation of Breast Cancer. <i>International Journal of Biomedical Imaging</i> , 2013, 2013, 1-14.	3.0	23
89	Novel Methods and Tracers for Breast Cancer Imaging. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 324-329.	2.5	52
90	Molecular imaging for monitoring treatment response in breast cancer patients. <i>European Journal of Pharmacology</i> , 2013, 717, 2-11.	1.7	14
91	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. <i>Future Oncology</i> , 2013, 9, 1653-1664.	1.1	10
92	Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging. <i>Nature Protocols</i> , 2013, 8, 1010-1018.	5.5	50
93	Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1171-1174.	2.8	57

#	ARTICLE	IF	CITATIONS
94	Effective dose to staff members in a positron emission tomography/CT facility using zirconium-89. <i>British Journal of Radiology</i> , 2013, 86, 20130318.	1.0	6
96	⁶⁴ Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1869-1875.	2.8	235
97	Pilot study of ⁶⁸ Ga-DOTA-F(ab ²) ₂ -trastuzumab in patients with breast cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 1157-1165.	0.5	68
98	Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake. <i>Cancer Research</i> , 2013, 73, 3347-3355.	0.4	103
99	Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2013, 54, 397-401.	2.8	47
100	Personalized Medicine: Through the Looking Glass of Functional Imaging. <i>Clinical Cancer Research</i> , 2013, 19, 4024-4026.	3.2	1
101	Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics. <i>Pharmacological Reviews</i> , 2013, 65, 1214-1256.	7.1	42
102	Review on Production of ⁸⁹ Zr in a Medical Cyclotron for PET Radiopharmaceuticals. <i>Journal of Nuclear Medicine Technology</i> , 2013, 41, 35-41.	0.4	65
103	New strategy for monitoring targeted therapy: molecular imaging. <i>International Journal of Nanomedicine</i> , 2013, 8, 3703.	3.3	30
104	⁶⁴ Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues. <i>PLoS ONE</i> , 2014, 9, e109866.	1.1	97
105	Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?. <i>Scientific World Journal</i> , The, 2014, 2014, 1-9.	0.8	5
106	Future Directions for the Early Detection of Recurrent Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 291-300.	1.2	14
107	Radionuclides for Imaging and Therapy in Oncology. , 2014, , 285-325.		8
108	⁸⁹ Zr-trastuzumab and ⁸⁹ Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 3945-3954.	3.2	105
109	ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹ Zr-RG7116. <i>MAbs</i> , 2014, 6, 1051-1058.	2.6	46
110	The role of systemic and targeted therapies in brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 93-103.	1.1	6
111	Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	103
112	Development of a ¹²⁴ I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. <i>International Journal of Oncology</i> , 2014, 44, 1998-2008.	1.4	14

#	ARTICLE	IF	CITATIONS
113	Preclinical evaluation of ⁸⁹ Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys. <i>MABs</i> , 2014, 6, 567-575.	2.6	32
114	Noninvasive positron emission tomography and fluorescence imaging of CD133+tumor stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E692-E701.	3.3	83
115	Imaging EGFR and HER2 by PET and SPECT: A Review. <i>Medicinal Research Reviews</i> , 2014, 34, 596-643.	5.0	55
116	A Phase I Dose-Escalation and Bioequivalence Study of a Trastuzumab Biosimilar in Healthy Male Volunteers. <i>Clinical Drug Investigation</i> , 2014, 34, 887-894.	1.1	31
117	Glypican-3 Targeting F(ab ²) for ⁸⁹ Zr PET of Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 2032-2037.	2.8	53
118	Considerations on absence of ⁶⁸ Ga-DOTA-F(ab ²)-trastuzumab tracer uptake in HER2-overexpressing tumor lesions. <i>Nuclear Medicine Communications</i> , 2014, 35, 785-786.	0.5	1
119	Painful knee prosthesis. <i>Nuclear Medicine Communications</i> , 2014, 35, 782-785.	0.5	0
120	PET imaging for brain tumor diagnostics. <i>Current Opinion in Neurology</i> , 2014, 27, 683-688.	1.8	32
121	Engineered antibody fragments for immuno-PET imaging of endogenous CD8 ⁺ T cells in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1108-1113.	3.3	148
122	Theranostic applications of antibodies in oncology. <i>Molecular Oncology</i> , 2014, 8, 799-812.	2.1	53
123	Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹ Zr-labeled anti-glypican-3 monoclonal antibody. <i>Biomaterials</i> , 2014, 35, 6964-6971.	5.7	39
125	First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the ¹¹¹ In-ABY-025 Affibody Molecule. <i>Journal of Nuclear Medicine</i> , 2014, 55, 730-735.	2.8	211
126	Immuno-PET Imaging of Tumor Endothelial Marker 8 (TEM8). <i>Molecular Pharmaceutics</i> , 2014, 11, 3996-4006.	2.3	21
127	Evaluation of ⁸⁹ Zr-pertuzumab in Breast Cancer Xenografts. <i>Molecular Pharmaceutics</i> , 2014, 11, 3988-3995.	2.3	64
128	Brain Metastases in Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1133-1140.	0.6	26
129	Radioimmunoconjugates for the Treatment of Cancer. <i>Seminars in Oncology</i> , 2014, 41, 613-622.	0.8	65
130	Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling. <i>Cancer Research</i> , 2014, 74, 5700-5710.	0.4	69
131	PET/CT imaging in cancer: Current applications and future directions. <i>Cancer</i> , 2014, 120, 3433-3445.	2.0	170

#	ARTICLE	IF	CITATIONS
132	Functional Imaging of Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Using ⁶⁴ Cu-DOTA-Trastuzumab PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 23-29.	2.8	142
133	Everolimus Reduces ⁸⁹ Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1087-1092.	2.8	56
134	Radionuclide imaging of drug delivery for patient selection in targeted therapy. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 175-185.	2.4	7
135	Molecular Imaging Reveals Trastuzumab-Induced Epidermal Growth Factor Receptor Downregulation In Vivo. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1002-1007.	2.8	16
136	Multicenter Harmonization of ⁸⁹ Zr PET/CT Performance. <i>Journal of Nuclear Medicine</i> , 2014, 55, 264-267.	2.8	63
137	Glypican-3â€“Targeted ⁸⁹ Zr PET Imaging of Hepatocellular Carcinoma: Where Antibody Imaging Dares to Tread. <i>Journal of Nuclear Medicine</i> , 2014, 55, 708-709.	2.8	5
138	Positron Emission Tomography Image-Guided Drug Delivery: Current Status and Future Perspectives. <i>Molecular Pharmaceutics</i> , 2014, 11, 3777-3797.	2.3	93
140	Clinical Translation of Molecular Imaging Agents Used in PET Studies of Cancer. <i>Advances in Cancer Research</i> , 2014, 124, 329-374.	1.9	6
141	Pilot study of ⁸⁹ Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. <i>EJNMMI Research</i> , 2014, 4, 35.	1.1	43
142	Antibody-based imaging strategies for cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 809-822.	2.7	103
143	C2c: turning cancer into chronic disease. <i>Genome Medicine</i> , 2014, 6, 38.	3.6	15
144	Alternative Chelator for ⁸⁹ Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4849-4860.	2.9	143
145	In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin ⁸⁹ Zr-PRS-110 PET Tracer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 665-671.	2.8	40
146	Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 493-499.	2.6	9
147	Glypican-3â€“Targeted ⁸⁹ Zr PET Imaging of Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 799-804.	2.8	56
148	The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. <i>British Journal of Radiology</i> , 2014, 87, 20140065.	1.0	31
149	¹¹¹ In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00011.	0.7	39
150	[⁶⁴ Cu]â€“labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 227-233.	0.5	16

#	ARTICLE	IF	CITATIONS
151	Dual in vivo Photoacoustic and Fluorescence Imaging of HER2 Expression in Breast Tumors for Diagnosis, Margin Assessment, and Surgical Guidance. <i>Molecular Imaging</i> , 2015, 14, 7290.2014.00043.	0.7	26
152	Breast cancer brain metastases: the last frontier. <i>Experimental Hematology and Oncology</i> , 2015, 4, 33.	2.0	124
153	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. <i>Journal of Pathology</i> , 2015, 237, 363-378.	2.1	98
154	⁸⁹ Zr- and Fe- Labeled Polymeric Micelles for Dual Modality PET and T ₁ -Weighted MR Imaging. <i>Advanced Healthcare Materials</i> , 2015, 4, 2137-2145.	3.9	21
155	Management of breast cancer brain metastases. <i>Breast Cancer Management</i> , 2015, 4, 279-283.	0.2	0
156	Targeted and Immunotherapeutic Approaches in Brain Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 67-74.	1.8	16
157	Treatment of early-stage HER2 breast cancer—an evolving field. <i>Ecancermedalscience</i> , 2015, 9, 523.	0.6	8
158	Cyclotron Production of High-Specific Activity ⁵⁵ Co and In Vivo Evaluation of the Stability of ⁵⁵ Co Metal-Chelate-Peptide Complexes. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00025.	0.7	22
159	Theragnostic Imaging Using Radiolabeled Antibodies and Tyrosine Kinase Inhibitors. <i>Scientific World Journal, The</i> , 2015, 2015, 1-6.	0.8	8
160	Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹ Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. <i>Oncotarget</i> , 2015, 6, 42081-42090.	0.8	31
161	Use of ¹⁸ F-2-Fluorodeoxyglucose to Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer. <i>ACS Central Science</i> , 2015, 1, 142-147.	5.3	85
162	⁸⁹ Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment. <i>Journal of Nuclear Medicine</i> , 2015, 56, 63-69.	2.8	100
163	Antibody Positron Emission Tomography Imaging in Anticancer Drug Development. <i>Journal of Clinical Oncology</i> , 2015, 33, 1491-1504.	0.8	93
164	⁸⁹ Zr-Labeled Versus ¹²⁴ I-Labeled $\hat{\pm}$ HER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1112-1118.	2.8	51
165	How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy. <i>JAMA Oncology</i> , 2015, 1, 421.	3.4	16
166	Developing biomarker-specific end points in lung cancer clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 135-146.	12.5	43
167	Radiopharmaceuticals as probes to characterize tumour tissue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 537-561.	3.3	14
168	High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. <i>MAbs</i> , 2015, 7, 96-109.	2.6	62

#	ARTICLE	IF	CITATIONS
169	Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer. <i>Oncologist</i> , 2015, 20, 94-104.	1.9	53
170	Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 288-301.	3.3	70
171	Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2591-2593.	0.8	6
172	PET/MR in Breast Cancer. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 304-321.	2.5	37
173	Cancer Stratification by Molecular Imaging. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4918-4946.	1.8	20
174	PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy. <i>PET Clinics</i> , 2015, 10, 495-505.	1.5	6
175	The Evolving Landscape of HER2 Targeting in Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1154.	3.4	107
176	PET Imaging of Breast Cancer. <i>PET Clinics</i> , 2015, 10, 159-195.	1.5	21
177	Mechanisms of action of therapeutic antibodies for cancer. <i>Molecular Immunology</i> , 2015, 67, 28-45.	1.0	136
178	Tumor Immunotargeting Using Innovative Radionuclides. <i>International Journal of Molecular Sciences</i> , 2015, 16, 3932-3954.	1.8	51
179	⁶⁴ Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. <i>EJNMMI Research</i> , 2015, 5, 8.	1.1	82
180	Novel ⁸⁹ Zr cell labeling approach for PET-based cell trafficking studies. <i>EJNMMI Research</i> , 2015, 5, 19.	1.1	107
181	Advancing Novel Molecular Imaging Agents from Preclinical Studies to First-in-Humans Phase I Clinical Trials in Academia—A Roadmap for Overcoming Perceived Barriers. <i>Bioconjugate Chemistry</i> , 2015, 26, 625-632.	1.8	12
182	Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [⁸⁹ Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model. <i>Molecular Imaging and Biology</i> , 2015, 17, 697-703.	1.3	11
183	Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope. <i>Radiology</i> , 2015, 276, 191-198.	3.6	20
184	Unsanctifying the sanctuary: challenges and opportunities with brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 639-651.	0.6	62
185	Gallium-68-Labeled Anti-HER2 Single-Chain Fv Fragment: Development and In Vivo Monitoring of HER2 Expression. <i>Molecular Imaging and Biology</i> , 2015, 17, 102-110.	1.3	28
186	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. <i>Cancer Research</i> , 2015, 75, 4364-4371.	0.4	55

#	ARTICLE	IF	CITATIONS
187	Alternative Protein Scaffolds as Novel Biotherapeutics. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 221-268.	0.2	6
188	TGF- β 2 Antibody Uptake in Recurrent High-Grade Glioma Imaged with ⁸⁹ Zr-Fresolimumab PET. Journal of Nuclear Medicine, 2015, 56, 1310-1314.	2.8	78
189	Multimodal imaging of bone metastases: From preclinical to clinical applications. Journal of Orthopaedic Translation, 2015, 3, 166-177.	1.9	15
190	Biobetters. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , .	0.2	3
191	Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?. Current Oncology Reports, 2015, 17, 46.	1.8	6
192	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 1700-1710.	5.1	108
193	<i>p</i> -SCN-Bn-HOPO: A Superior Bifunctional Chelator for ⁸⁹ Zr ImmunoPET. Bioconjugate Chemistry, 2015, 26, 2579-2591.	1.8	104
194	Systemic Therapy of Brain Metastases. Current Neurology and Neuroscience Reports, 2015, 15, 518.	2.0	46
195	A 21-Year-Old Patient With a HER2-Positive Colorectal Cancer. Gastroenterology, 2015, 148, 20-21.	0.6	5
196	Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with ⁸⁹ Zr ⁴⁺ : comparison with desferrioxamine-B. Dalton Transactions, 2015, 44, 4884-4900.	1.6	72
197	Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Annals of Oncology, 2015, 26, 113-119.	0.6	327
198	Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cellular Oncology (Dordrecht), 2015, 38, 49-64.	2.1	23
199	Kit for the preparation of ¹¹¹ In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin). Applied Radiation and Isotopes, 2015, 95, 135-142.	0.7	13
200	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸ Ga]ABY-025 Affibody PET/CT. Theranostics, 2016, 6, 262-271.	4.6	204
201	Cancer and the metastatic substrate. Ecancermedicalsecience, 2016, 10, 701.	0.6	17
202	Brain Metastases from Breast Cancer. , 2016, , 321-333.		0
203	Targeted Therapy in Brain Metastases: Ready for Primetime?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e123-e130.	1.8	35
204	Targeted Therapies for Brain Metastases from Breast Cancer. International Journal of Molecular Sciences, 2016, 17, 1543.	1.8	67

#	ARTICLE	IF	CITATIONS
205	Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies. <i>Theranostics</i> , 2016, 6, 862-874.	4.6	71
206	Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?. <i>Frontiers in Pharmacology</i> , 2016, 7, 131.	1.6	152
207	Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 528-533.	7.2	42
208	Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF- α experience to oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 419-431.	2.3	74
209	Macrocyclic-Based Hydroxamate Ligands for Complexation and Immunoconjugation of ⁸⁹ Zirconium for Positron Emission Tomography (PET) Imaging. <i>ChemPlusChem</i> , 2016, 81, 274-281.	1.3	55
210	Novel Imaging Based Biomarkers in Breast Cancer. , 2016, , 187-206.		1
212	PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management. <i>PET Clinics</i> , 2016, 11, 305-318.	1.5	12
213	Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸ Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1505-1511.	2.8	61
214	Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside. <i>Journal of Nuclear Medicine</i> , 2016, 57, 996-1001.	2.8	6
215	Imaging metabolic heterogeneity in cancer. <i>Molecular Cancer</i> , 2016, 15, 4.	7.9	64
216	PET imaging of epidermal growth factor receptor expression in tumours using ⁸⁹ Zr-labelled ZEGFR:2377 affibody molecules. <i>International Journal of Oncology</i> , 2016, 48, 1325-1332.	1.4	50
217	Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys. <i>Molecular Imaging and Biology</i> , 2016, 18, 768-775.	1.3	12
218	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule ⁶⁸ Ga-ABY-025 in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 867-871.	2.8	88
219	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2016, , 535-573.		0
220	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using ⁸⁹ Zr-Trastuzumab PET/CT. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1523-1528.	2.8	146
221	Synthesis and systematic evaluation of symmetric sulfonated centrally C C bonded cyanine near-infrared dyes for protein labelling. <i>Dyes and Pigments</i> , 2016, 132, 7-19.	2.0	36
222	Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. <i>Clinical and Translational Science</i> , 2016, 9, 74-88.	1.5	67
223	Phase 1 Evaluation of [⁶⁴ Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. <i>Molecular Imaging and Biology</i> , 2016, 18, 446-453.	1.3	40

#	ARTICLE	IF	CITATIONS
224	Radiolabeled Agents for Molecular Imaging and/or Therapy. <i>Imaging in Medical Diagnosis and Therapy</i> , 2016, , 385-406.	0.0	0
225	A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies. <i>Chemical Communications</i> , 2016, 52, 11889-11892.	2.2	77
226	Progress of Multimodal Molecular Imaging Technology in Diagnosis of Tumor. <i>Chinese Journal of Analytical Chemistry</i> , 2016, 44, 1609-1618.	0.9	11
228	Focused ultrasound induced hyperthermia accelerates and increases the uptake of anti-HER-2 antibodies in a xenograft model. <i>Pharmacological Research</i> , 2016, 114, 144-151.	3.1	16
229	Molecular imaging using PET and SPECT for identification of breast cancer subtypes. <i>Nuclear Medicine Communications</i> , 2016, 37, 1116-1124.	0.5	21
231	Synthesis and Characterization of ⁸⁹ Zr-Labeled Ultrasmall Nanoparticles. <i>Molecular Pharmaceutics</i> , 2016, 13, 2596-2601.	2.3	24
232	[⁸⁹ Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 952-959.	1.3	103
233	^{99m} Tc-anti-TNF- α antibody for the imaging of disease activity in pulmonary sarcoidosis. <i>European Respiratory Journal</i> , 2016, 47, 1198-1207.	3.1	21
234	Molecular imagingâ€™s current role in cancer. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 295-299.	0.2	17
235	Immuno-PET Imaging of CD30-Positive Lymphoma Using ⁸⁹ Zr-Desferrioxamineâ€™Labeled CD30-Specific AC-10 Antibody. <i>Journal of Nuclear Medicine</i> , 2016, 57, 96-102.	2.8	33
236	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibodyâ€™Drug Conjugate Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 1642-1652.	3.2	74
237	Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. <i>MAbs</i> , 2016, 8, 229-245.	2.6	127
238	HER2 imaging in the ZEPHIR study. <i>Annals of Oncology</i> , 2016, 27, 555-557.	0.6	7
239	Current advances in ligand design for inorganic positron emission tomography tracers ⁶⁸ Ga, ⁶⁴ Cu, ⁸⁹ Zr and ⁴⁴ Sc. <i>Dalton Transactions</i> , 2016, 45, 15702-15724.	1.6	81
240	Molecular Imaging of Biomarkers in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 53S-59S.	2.8	56
241	Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine. <i>Journal of Nuclear Medicine</i> , 2016, 57, 60S-68S.	2.8	33
242	Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2. <i>Journal of Nuclear Medicine</i> , 2016, 57, 81S-88S.	2.8	43
243	Imaging quality of ⁴⁴ Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET. <i>Applied Radiation and Isotopes</i> , 2016, 110, 129-133.	0.7	43

#	ARTICLE	IF	CITATIONS
244	Preclinical Pharmacokinetics Evaluation of Anti-heparin-binding EGF-like Growth Factor (HB-EGF) Monoclonal Antibody Using Cynomolgus Monkeys via ⁸⁹ Zr-immuno-PET Study and the Determination of Drug Concentrations in Serum and Cerebrospinal Fluid. <i>Pharmaceutical Research</i> , 2016, 33, 476-486.	1.7	5
245	Microfluidic Preparation of a ⁸⁹ Zr-Labeled Trastuzumab Single-Patient Dose. <i>Journal of Nuclear Medicine</i> , 2016, 57, 747-752.	2.8	16
246	Clinical impact of tumour biology in the management of gastroesophageal cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 348-360.	12.5	132
247	Preclinical Evaluation of ¹⁸ F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2016, 57, 967-973.	2.8	68
248	Development of Companion Diagnostics. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 47-56.	2.5	40
249	Semi-automated production of ⁸⁹ Zr-oxalate/ ⁸⁹ Zr-chloride and the potential of ⁸⁹ Zr-chloride in radiopharmaceutical compounding. <i>Applied Radiation and Isotopes</i> , 2016, 107, 317-322.	0.7	22
250	An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. <i>Cancer Research</i> , 2016, 76, 73-82.	0.4	265
251	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. <i>Annals of Oncology</i> , 2016, 27, 619-624.	0.6	269
252	Molecular imaging using PET for breast cancer. <i>Breast Cancer</i> , 2016, 23, 24-32.	1.3	25
253	Phase I Study of ⁶⁸ Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 27-33.	2.8	317
254	Breast PET/MR Imaging. <i>Radiologic Clinics of North America</i> , 2017, 55, 579-589.	0.9	14
255	Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 313-324.	0.6	1
256	Personalized Pathway-Activated Systems Imaging in Oncology. , 2017, , .		1
257	Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation. <i>Molecular Imaging and Biology</i> , 2017, 19, 867-877.	1.3	54
258	Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 581-591.	1.1	52
259	Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. <i>Cancer Research</i> , 2017, 77, 3931-3941.	0.4	91
260	Exploiting the biosynthetic machinery of <i>Streptomyces pilosus</i> to engineer a water-soluble zirconium(^{iv}) chelator. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 5719-5730.	1.5	33
261	In Vivo Imaging of the Programmed Death Ligand 1 by ¹⁸ F PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1852-1857.	2.8	84

#	ARTICLE	IF	CITATIONS
262	The Use of Microdosing in the Development of Small Organic and Protein Therapeutics. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1188-1195.	2.8	20
263	Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer. <i>PET Clinics</i> , 2017, 12, 269-288.	1.5	49
264	History and future technical innovation in positron emission tomography. <i>Journal of Medical Imaging</i> , 2017, 4, 011013.	0.8	165
265	⁶⁴ Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4190-4202.	3.2	280
266	Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1337-1346.	3.3	39
267	Development of Lu ¹⁷⁷ trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. <i>International Journal of Cancer</i> , 2017, 140, 938-947.	2.3	50
268	¹⁸ F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3053-3060.	3.2	66
269	Making Molecular Imaging a Clinical Tool for Precision Oncology. <i>JAMA Oncology</i> , 2017, 3, 695.	3.4	63
270	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	5.1	153
271	Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting. <i>Seminars in Oncology Nursing</i> , 2017, 33, 425-439.	0.7	6
272	Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer?. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1835-1845.	0.5	4
273	Theranostics Using Antibodies and Antibody-Related Therapeutics. <i>Journal of Nuclear Medicine</i> , 2017, 58, 83S-90S.	2.8	85
274	⁸⁹ Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2017, 42, 912-917.	0.7	81
275	⁸⁹ Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6128-6137.	3.2	51
276	Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology. <i>Methods</i> , 2017, 130, 23-35.	1.9	28
277	⁸⁹ Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art ⁸⁹ Zr Radiochemistry. <i>Bioconjugate Chemistry</i> , 2017, 28, 2211-2223.	1.8	146
278	Pretargeted PET Imaging Using a Bioorthogonal ¹⁸ F-Labeled <i>trans</i> -Cyclooctene in an Ovarian Carcinoma Model. <i>Bioconjugate Chemistry</i> , 2017, 28, 2915-2920.	1.8	38
279	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. <i>Scientific Reports</i> , 2017, 7, 14780.	1.6	17

#	ARTICLE	IF	CITATIONS
280	Earth, air, fire and water: A targetry quartet. AIP Conference Proceedings, 2017, , .	0.3	1
281	Targeting PI3K/AKT/mTOR Pathway. , 2017, , 787-793.		0
282	In vivo near-infrared imaging of ErbB2 expressing breast tumors with dual-axes confocal endomicroscopy using a targeted peptide. Scientific Reports, 2017, 7, 14404.	1.6	10
283	Evolution of anti-HER2 therapies for cancer treatment. Cancer Treatment Reviews, 2017, 59, 1-21.	3.4	73
284	Current challenges in the management of breast cancer brain metastases. Seminars in Oncology, 2017, 44, 85-100.	0.8	44
285	Multifunctional Desferrichrome Analogues as Versatile ⁸⁹ Zr(IV) Chelators for ImmunoPET Probe Development. Molecular Pharmaceutics, 2017, 14, 2831-2842.	2.3	41
286	Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative ⁸⁹ Zr-ImmunoPET. Molecular Cancer Therapeutics, 2017, 16, 134-142.	1.9	30
287	Imaging Biomarkers. , 2017, , .		7
288	The evolving clinical management of cerebral metastases. European Journal of Surgical Oncology, 2017, 43, 1173-1185.	0.5	11
289	Development and preclinical studies of ⁶⁴ Cu-NOTA-pertuzumab F(ab ²) for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT. MABs, 2017, 9, 154-164.	2.6	39
290	Molecular imaging in oncology drug development. Drug Discovery Today, 2017, 22, 140-147.	3.2	11
291	⁶⁸ Ga-DTPA Anti-HER2 positron emission tomography/CT successfully predicts the overexpression of human epidermal growth factor receptor in lung metastases from breast cancer. BJR case Reports, 2017, 3, 20160136.	0.1	1
292	Preparation and Identification of HER2 Radioactive Ligands and Imaging Study of Breast Cancer-Bearing Nude Mice. Translational Oncology, 2017, 10, 518-526.	1.7	6
293	Immuno-PET for Clinical Theranostic Approaches. International Journal of Molecular Sciences, 2017, 18, 57.	1.8	50
294	Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context. International Journal of Molecular Sciences, 2017, 18, 152.	1.8	20
295	Review: Receptor Targeted Nuclear Imaging of Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 260.	1.8	27
296	Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with ⁶⁴ Cu Using NOTA and NODAGA. Contrast Media and Molecular Imaging, 2017, 2017, 1-12.	0.4	14
297	Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics, 2017, 7, 2111-2133.	4.6	12

#	ARTICLE	IF	CITATIONS
298	Performance of ⁸⁹ Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. PLoS ONE, 2017, 12, e0169828.	1.1	50
299	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget, 2017, 8, 41932-41946.	0.8	95
300	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 45-56.	1.8	24
302	Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging, 2018, 17, 153601211774538.	0.7	57
303	PET/MR Imaging: Current and Emerging Applications. , 2018, , .		4
304	Imaging of human epidermal growth factor receptors for patient selection and response monitoring “ From PET imaging and beyond. Cancer Letters, 2018, 419, 139-151.	3.2	26
305	Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 672-692.	0.5	26
306	Biodistribution and PET imaging of ⁸⁹ -zirconium labeled cerium oxide nanoparticles synthesized with several surface coatings. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1429-1440.	1.7	24
307	Systemic therapy for brain metastases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 137-153.	1.0	23
308	Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies. Cancer and Metastasis Reviews, 2018, 37, 125-145.	2.7	13
309	A Dual Reporter Iodinated Labeling Reagent for Cancer Positron Emission Tomography Imaging and Fluorescence-Guided Surgery. Journal of Medicinal Chemistry, 2018, 61, 1636-1645.	2.9	22
310	⁸⁹ Zr-ImmunoPET companion diagnostics and their impact in clinical drug development. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 727-738.	0.5	42
311	PET radiometals for antibody labeling. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 636-651.	0.5	43
312	Pretargeted Immuno-PET Based on Bioorthogonal Chemistry for Imaging EGFR Positive Colorectal Cancer. Bioconjugate Chemistry, 2018, 29, 250-254.	1.8	28
313	Evaluation of [⁸⁹ Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Research and Treatment, 2018, 169, 523-530.	1.1	59
314	Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Cancer Research, 2018, 78, 1820-1832.	0.4	69
315	Molecular Imaging in Cancer Drug Development. Journal of Nuclear Medicine, 2018, 59, 726-732.	2.8	50
316	Management of Central Nervous System Metastases in Breast Cancer. , 2018, , 942-960.e7.		0

#	ARTICLE	IF	CITATIONS
317	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e20-e32.	5.1	87
318	Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. <i>Journal of Neuro-Oncology</i> , 2018, 137, 295-302.	1.4	41
319	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. <i>Journal of Nuclear Medicine</i> , 2018, 59, 885-891.	2.8	101
320	Receptor Occupancy Imaging Studies in Oncology Drug Development. <i>AAPS Journal</i> , 2018, 20, 43.	2.2	12
321	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹ Zr-Trastuzumab in Patients with Esophagogastric Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 161-166.	2.8	96
322	ImmunoPET Imaging of ¹²⁵ I Expression Using an Engineered Anti- ¹²⁵ I Cys-diabody Site-Specifically Radiolabeled with Cu-64: Considerations for Optimal Imaging with Antibody Fragments. <i>Molecular Imaging and Biology</i> , 2018, 20, 103-113.	1.3	14
323	Preclinical Development of CD38-Targeted [⁸⁹ Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 216-222.	2.8	50
324	⁸⁹ Zr for antibody labeling and in vivo studies – A comparison between liquid and solid target production. <i>Nuclear Medicine and Biology</i> , 2018, 58, 1-7.	0.3	8
325	Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 65-77.	1.8	11
326	Targeting HER2 by Combination Therapies. <i>Journal of Clinical Oncology</i> , 2018, 36, 808-811.	0.8	13
327	⁸⁹ Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I. <i>Oncotarget</i> , 2018, 9, 17117-17132.	0.8	31
328	⁶⁶ Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?. <i>Molecules</i> , 2018, 23, 2575.	1.7	9
329	⁸⁹ Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. <i>Nature Medicine</i> , 2018, 24, 1852-1858.	15.2	468
330	Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. <i>Nature Communications</i> , 2018, 9, 5137.	5.8	78
331	Noninvasive Detection of HER2 Expression in Gastric Cancer by ⁶⁴ Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients. <i>Molecular Pharmaceutics</i> , 2018, 15, 5174-5182.	2.3	18
332	Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. <i>Nature Communications</i> , 2018, 9, 4141.	5.8	126
333	PET Imaging Utilizing ⁸⁹ Zr-labeled Human Antibody Variant and Theranostic Technologies Provided by a Novel DDS Carrier. <i>Drug Delivery System</i> , 2018, 33, 214-222.	0.0	1
334	Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for ⁶⁴ Cu-Based PET Imaging. <i>Molecular Pharmaceutics</i> , 2018, 15, 5556-5564.	2.3	28

#	ARTICLE	IF	CITATIONS
335	Comparative biodistribution analysis across four different ⁸⁹ Zr-monoclonal antibody tracers – The first step towards an imaging warehouse. <i>Theranostics</i> , 2018, 8, 4295-4304.	4.6	46
336	Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model. <i>Scientific Reports</i> , 2018, 8, 13735.	1.6	15
337	A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant ⁸⁹ Zr-immuno-PET agents. <i>Dalton Transactions</i> , 2018, 47, 13214-13221.	1.6	11
338	Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging. <i>MAbs</i> , 2018, 10, 1269-1280.	2.6	8
339	Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 691-705.	1.7	38
340	PET imaging for assessing tumor response to therapy. <i>Journal of Surgical Oncology</i> , 2018, 118, 362-373.	0.8	7
341	Dedicated Breast Gamma Camera Imaging and Breast PET. <i>PET Clinics</i> , 2018, 13, 363-381.	1.5	35
342	Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer. <i>PET Clinics</i> , 2018, 13, 423-435.	1.5	21
343	Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with ⁸⁹ Zr-Labeled Trastuzumab-DM1: A Comparison with ⁸⁹ Zr-Labeled Trastuzumab. <i>Molecular Pharmaceutics</i> , 2018, 15, 3383-3393.	2.3	16
344	PET Imaging of Receptor Tyrosine Kinases in Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1625-1636.	1.9	35
345	Management of leptomeningeal metastasis in breast cancer. <i>Clinical Neurology and Neurosurgery</i> , 2018, 172, 151-159.	0.6	15
346	Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. <i>BMC Cancer</i> , 2018, 18, 97.	1.1	40
347	Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. <i>EJNMMI Research</i> , 2018, 8, 6.	1.1	11
348	I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. <i>EJNMMI Research</i> , 2018, 8, 20.	1.1	17
349	Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. <i>Annals of Translational Medicine</i> , 2018, 6, 163-163.	0.7	86
350	Excitation functions for (p,x) reactions of niobium in the energy range of Ep = 40–90 MeV. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2018, 429, 53-74.	0.6	15
351	Brain metastases: neuroimaging. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 89-112.	1.0	123
352	Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 148-163.	2.3	60

#	ARTICLE	IF	CITATIONS
353	The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 20-26.	2.0	10
354	<p>Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 5911-5924.	3.3	29
355	Site-specifically labeled ⁸⁹ Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model. <i>Theranostics</i> , 2019, 9, 4409-4420.	4.6	41
357	Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab. <i>Molecules</i> , 2019, 24, 3907.	1.7	8
358	Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer. <i>BMC Cancer</i> , 2019, 19, 1000.	1.1	19
359	Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer. <i>Cancers</i> , 2019, 11, 1614.	1.7	8
360	¹¹¹ In- and ²²⁵ Ac-Labeled Cixutumumab for Imaging and Î±-Particle Radiotherapy of IGF-1R Positive Triple-Negative Breast Cancer. <i>Molecular Pharmaceutics</i> , 2019, 16, 4807-4816.	2.3	23
361	Imaging of HER2 with [⁸⁹ Zr]pertuzumab in Response to T-DM1 Therapy. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2019, 34, 209-217.	0.7	20
362	Pharmacokinetics and Biodistribution of a [⁸⁹ Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Molecular Pharmaceutics</i> , 2019, 16, 3083-3090.	2.3	26
363	Immunoglobulins as Radiopharmaceutical Vectors. , 2019, , 163-179.		3
364	Molecular Imaging Companion Diagnostics. , 2019, , 201-228.		2
365	Blocking of Glucagonlike Peptide-1 Receptors in the Exocrine Pancreas Improves Specificity for Î²-Cells in a Mouse Model of Type 1 Diabetes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1635-1641.	2.8	14
366	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. <i>Scientific Reports</i> , 2019, 9, 6779.	1.6	8
367	Targeting Molecular Pathways in Intracranial Metastatic Disease. <i>Frontiers in Oncology</i> , 2019, 9, 99.	1.3	10
368	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. <i>Biomaterials</i> , 2019, 203, 73-85.	5.7	19
369	Systemic Therapy of Central Nervous System Metastases of Breast Cancer. <i>Current Oncology Reports</i> , 2019, 21, 49.	1.8	26
370	Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. <i>Clinical Cancer Research</i> , 2019, 25, 3946-3953.	3.2	46
371	Click Chemistry in Radiopharmaceutical Chemistry. , 2019, , 467-479.		0

#	ARTICLE	IF	CITATIONS
372	Central Nervous System Metastases in HER2-Positive Breast Cancer. , 2019, , 75-93.		0
373	Analogues of desferrioxamine B (DFOB) with new properties and new functions generated using precursor-directed biosynthesis. <i>BioMetals</i> , 2019, 32, 395-408.	1.8	8
374	The Impact of Fc γ RI Binding on Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1174-1182.	2.8	37
375	Current Treatment Options for Breast Cancer Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2019, 20, 19.	1.3	10
376	^{89}Zr -labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake. <i>Clinical Cancer Research</i> , 2019, 25, 3517-3527.	3.2	34
377	Brain Access of Monoclonal Antibodies as Imaged and Quantified by ^{89}Zr -Antibody PET: Perspectives for Treatment of Brain Diseases. <i>Journal of Nuclear Medicine</i> , 2019, 60, 615-616.	2.8	11
378	Current state of clinical trials in breast cancer brain metastases. <i>Neuro-Oncology Practice</i> , 2019, 6, 392-401.	1.0	16
379	Breast cancer patients with brain metastasis undergoing GKRS. <i>Breast Cancer</i> , 2019, 26, 147-153.	1.3	5
380	Assessment of exposure after injection of $^{99\text{mTc}}$ -labeled intact monoclonal antibodies and their fragments into humans. <i>Radiological Physics and Technology</i> , 2019, 12, 96-104.	1.0	11
381	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. <i>Lung Cancer</i> , 2019, 128, 105-112.	0.9	126
382	Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of ^{64}Cu -Trastuzumab. <i>Molecular Pharmaceutics</i> , 2019, 16, 1065-1073.	2.3	11
383	Tumor cell heterogeneity and resistance; report from the 2018 Coffey&Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2019, 79, 244-258.	1.2	13
384	PET/MRI in Breast Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 328-342.	1.9	31
385	HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody"Drug Conjugate Drug Development in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 775-786.	3.2	36
386	^{89}Zr -cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 849-859.	3.3	22
387	Construction of ^{124}I -trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients. <i>Gastric Cancer</i> , 2020, 23, 614-626.	2.7	23
388	Multimodal Nanocarrier Probes Reveal Superior Biodistribution Quantification by Isotopic Analysis over Fluorescence. <i>ACS Nano</i> , 2020, 14, 509-523.	7.3	23
389	Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1054-1064.	3.2	15

#	ARTICLE	IF	CITATIONS
390	Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. <i>Theranostics</i> , 2020, 10, 938-955.	4.6	84
391	Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095372.	1.4	12
392	Mechanistic Modeling of the Relative Biological Effectiveness of Boron Neutron Capture Therapy. <i>Cells</i> , 2020, 9, 2302.	1.8	10
393	Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma. <i>Pharmaceuticals</i> , 2020, 13, 287.	1.7	0
394	Nanobodies as non-invasive imaging tools. <i>Immuno-Oncology Technology</i> , 2020, 7, 2-14.	0.2	26
395	Immune-Directed Molecular Imaging Biomarkers. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 584-603.	2.5	3
396	Structural Characterization of the Solution Chemistry of Zirconium(IV) Desferrioxamine: A Coordination Sphere Completed by Hydroxides. <i>Inorganic Chemistry</i> , 2020, 59, 17443-17452.	1.9	13
397	Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1301.	1.3	55
398	Glycan-Based Near-infrared Fluorescent (NIRF) Imaging of Gastrointestinal Tumors: a Preclinical Proof-of-Concept In Vivo Study. <i>Molecular Imaging and Biology</i> , 2020, 22, 1511-1522.	1.3	6
399	A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89. <i>Inorganic Chemistry</i> , 2020, 59, 11715-11727.	1.9	20
400	Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 555-560.	1.1	4
401	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , 2020, 16, 557-574.	4.9	104
402	Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases. <i>Annals of Oncology</i> , 2020, 31, 1279-1281.	0.6	3
403	HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker. <i>Neuro-Oncology</i> , 2020, 22, 1625-1636.	0.6	23
404	ImmunoPET in Multiple Myeloma—What? So What? Now What?. <i>Cancers</i> , 2020, 12, 1467.	1.7	8
405	PET Molecular Imaging as a Tool for Precision Oncology. <i>Radiology</i> , 2020, 296, 379-380.	3.6	2
406	Advances in Management of Brain and Leptomeningeal Metastases. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 26.	2.0	10
407	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹ Zr-Pertuzumab PET/CT. <i>Radiology</i> , 2020, 296, 370-378.	3.6	40

#	ARTICLE	IF	CITATIONS
408	Current Perspectives on ⁸⁹ Zr-PET Imaging. International Journal of Molecular Sciences, 2020, 21, 4309.	1.8	70
409	(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer. Pharmaceuticals, 2020, 13, 39.	1.7	10
410	A Systematic Evaluation of Antibody Modification and ⁸⁹ Zr-Radiolabeling for Optimized Immuno-PET. Bioconjugate Chemistry, 2021, 32, 1177-1191.	1.8	26
411	ImmunoPET: Concept, Design, and Applications. Chemical Reviews, 2020, 120, 3787-3851.	23.0	263
412	Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. Cancers, 2020, 12, 781.	1.7	8
413	Affibody Molecules as Targeting Vectors for PET Imaging. Cancers, 2020, 12, 651.	1.7	56
414	Application of PET Tracers in Molecular Imaging for Breast Cancer. Current Oncology Reports, 2020, 22, 85.	1.8	28
415	Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with ⁸⁹ Zr-oxine PET-CT. Stem Cell Research and Therapy, 2020, 11, 256.	2.4	32
416	Total-Body PET and Highly Stable Chelators Together Enable Meaningful ⁸⁹ Zr-Antibody PET Studies up to 30 Days After Injection. Journal of Nuclear Medicine, 2020, 61, 453-460.	2.8	66
417	Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Research and Treatment, 2020, 180, 279-300.	1.1	52
418	The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors. International Journal of Molecular Sciences, 2020, 21, 1029.	1.8	20
419	Current approaches to the management of brain metastases. Nature Reviews Clinical Oncology, 2020, 17, 279-299.	12.5	276
420	Ovarian Cancer Targeted Theranostics. Frontiers in Oncology, 2019, 9, 1537.	1.3	27
421	The Influence of Glycans-Specific Bioconjugation on the ⁸⁹ Zr-DFO Binding and <i>In vivo</i> Performance of ⁸⁹ Zr-DFO-Pertuzumab. Theranostics, 2020, 10, 1746-1757.	4.6	31
422	Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging. Molecular Diagnosis and Therapy, 2020, 24, 191-200.	1.6	8
423	Radiolabelled Trastuzumab PET/CT imaging: a promising non-invasive tool for the <i>in vivo</i> assessment of HER2 status in breast cancer patients. Clinical and Translational Imaging, 2020, 8, 95-105.	1.1	2
424	Preclinical Targeted ¹²⁵ I- and ¹²⁵ I-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers, 2020, 12, 1017.	1.7	43
425	Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1628.	3.3	24

#	ARTICLE	IF	CITATIONS
426	First In-Human Medical Imaging with a PASylated ⁸⁹ Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 114-119.	0.6	20
427	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. <i>Radiology</i> , 2020, 295, 606-615.	3.6	73
428	Impact of ⁶⁸ Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 161-175.	3.3	19
429	Review: PET imaging with macro- and middle-sized molecular probes. <i>Nuclear Medicine and Biology</i> , 2021, 92, 156-170.	0.3	14
430	Recent advances in nanoscale materials for antibody-based cancer theranostics. <i>Biosensors and Bioelectronics</i> , 2021, 173, 112787.	5.3	12
431	Expanding PET-applications in life sciences with positron-emitters beyond fluorine-18. <i>Nuclear Medicine and Biology</i> , 2021, 92, 241-269.	0.3	19
432	HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1371-1389.	3.3	63
433	Treatment strategies for breast cancer brain metastases. <i>British Journal of Cancer</i> , 2021, 124, 142-155.	2.9	117
434	The Role of ⁸⁹ Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. <i>Journal of Nuclear Medicine</i> , 2021, 62, 438-445.	2.8	39
435	Brain metastasis models: What should we aim to achieve better treatments?. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 79-99.	6.6	13
436	In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry. <i>Bioconjugate Chemistry</i> , 2021, 32, 121-132.	1.8	20
437	PET/CT Imaging of ⁸⁹ Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys. <i>Molecular Imaging and Biology</i> , 2021, 23, 250-259.	1.3	18
438	Phase I Study of ^{99m} Tc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 493-499.	2.8	41
439	Nanobody Conjugates for Targeted Cancer Therapy and Imaging. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110101.	0.8	19
440	Antibodies and antibody constructs as radiopharmaceuticals. , 2021, , .		0
441	Improved image reconstruction of ⁸⁹ Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm. <i>EJNMMI Physics</i> , 2021, 8, 6.	1.3	7
442	A Novel ⁸⁹ Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): α -Lactosome Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy. <i>Life</i> , 2021, 11, 158.	1.1	7
443	Lipophilicity and Click Reactivity Determine the Performance of Bioorthogonal Tetrazine Tools in Pretargeted <i>In Vivo</i> Chemistry. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 824-833.	2.5	45

#	ARTICLE	IF	CITATIONS
444	Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer. <i>Molecular Imaging</i> , 2021, 2021, 1-12.	0.7	2
445	Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. <i>Pharmaceutics</i> , 2021, 13, 422.	2.0	16
446	Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3493.	1.8	4
447	On the role of Brain Imaging in drug development for psychiatry. <i>Current Clinical Pharmacology</i> , 2021, 16, 46-71.	0.2	0
448	[⁸⁹ Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models. <i>Molecules</i> , 2021, 26, 1568.	1.7	8
449	Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives. <i>Cancers</i> , 2021, 13, 1078.	1.7	41
450	Theranostic Advances in Breast Cancer in Nuclear Medicine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4597.	1.8	38
451	PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3663.	1.8	18
452	Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. <i>Cancers</i> , 2021, 13, 2888.	1.7	26
453	Preparation of ⁸⁹ Zr Solutions for Radiopharmaceuticals Synthesis. <i>Radiochemistry</i> , 2021, 63, 369-383.	0.2	4
454	Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. <i>Cancers</i> , 2021, 13, 2927.	1.7	54
455	Reaction of [¹⁸ F]Fluoride at Heteroatoms and Metals for Imaging of Peptides and Proteins by Positron Emission Tomography. <i>Frontiers in Chemistry</i> , 2021, 9, 687678.	1.8	17
456	Investigation of ¹⁸ F and ⁸⁹ Zr Isotopes Self-Absorption and Dose Rate Parameters for PET Imaging. <i>Dose-Response</i> , 2021, 19, 155932582110284.	0.7	1
457	Theranostics in Brain Tumors. <i>PET Clinics</i> , 2021, 16, 397-418.	1.5	9
458	Production, Purification, and Applications of a Potential Theranostic Pair: Cobalt-55 and Cobalt-58m. <i>Diagnostics</i> , 2021, 11, 1235.	1.3	10
459	Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models. <i>Molecular Imaging and Biology</i> , 2021, 23, 914-928.	1.3	3
460	The blood–tumour barrier in cancer biology and therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 696-714.	12.5	112
461	The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. <i>Seminars in Cancer Biology</i> , 2021, 72, 185-197.	4.3	27

#	ARTICLE	IF	CITATIONS
462	Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. <i>Drug Discovery Today</i> , 2021, 26, 1980-1990.	3.2	3
463	Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease. <i>JAMA Oncology</i> , 2021, 7, 1220.	3.4	5
464	Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic. <i>Frontiers in Oncology</i> , 2021, 11, 698425.	1.3	14
465	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2667-2675.	0.8	58
466	Analysis of absorbed dose in radioimmunotherapy with ¹⁷⁷ Lu-trastuzumab using two different imaging scenarios: a pilot study. <i>Nuclear Medicine Communications</i> , 2021, 42, 1382-1395.	0.5	5
467	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , 2021, 41, 757-773.	1.1	1
468	⁸⁹ Zr as a promising radionuclide and its applications for effective cancer imaging. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2021, 330, 15-28.	0.7	6
469	HER2 Receptor Conversion Is a strong Survival Predictor in Patients with Breast Cancer Brain Metastases. <i>World Neurosurgery</i> , 2021, 152, e332-e343.	0.7	4
470	Potential and pitfalls of ⁸⁹ Zr-immuno-PET to assess target status: ⁸⁹ Zr-trastuzumab as an example. <i>EJNMMI Research</i> , 2021, 11, 74.	1.1	6
471	HER3 PET Imaging: ⁶⁸ Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to ⁸⁹ Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. <i>Cancers</i> , 2021, 13, 4791.	1.7	6
472	ImmunoPET: harnessing antibodies for imaging immune cells. <i>Molecular Imaging and Biology</i> , 2022, 24, 181-197.	1.3	15
473	⁸⁹ Zr-PET imaging in humans: a systematic review. <i>Clinical and Translational Imaging</i> , 2022, 10, 23-36.	1.1	15
474	Key metrics to expanding the pipeline of successful antibody-drug conjugates. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 803-812.	4.0	14
475	Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives. <i>Coordination Chemistry Reviews</i> , 2021, 445, 214104.	9.5	59
476	Strategies to enhance monoclonal antibody uptake and distribution in solid tumors. <i>Cancer Biology and Medicine</i> , 2021, 18, 649-664.	1.4	16
477	Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. <i>Theranostics</i> , 2021, 11, 5525-5538.	4.6	33
478	Noninvasive Imaging of Cancer Immunotherapy. <i>Nanotheranostics</i> , 2021, 5, 90-112.	2.7	22
480	Hybrid Imaging for Breast Malignancies. , 2019, , 543-570.		1

#	ARTICLE	IF	CITATIONS
481	The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 894-904.	0.6	95
484	Simulation study of quantitative precision of the PET/X dedicated breast PET scanner. <i>Journal of Medical Imaging</i> , 2017, 4, 1.	0.8	5
485	The PET/X dedicated breast-PET scanner for optimizing cancer therapy. , 2018, , .		3
486	Multimodal image-guided surgery of HER2-positive breast cancer using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model. <i>EJNMMI Research</i> , 2019, 9, 98.	1.1	9
487	Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 16.	1.8	38
488	Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis. <i>Chemical and Pharmaceutical Bulletin</i> , 2020, 68, 560-566.	0.6	24
489	Use of a Single Hybrid Imaging Agent for Integration of Target Validation with In Vivo and Ex Vivo Imaging of Mouse Tumor Lesions Resembling Human DCIS. <i>PLoS ONE</i> , 2013, 8, e48324.	1.1	20
490	Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET. <i>PLoS ONE</i> , 2013, 8, e77476.	1.1	31
491	Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice. <i>PLoS ONE</i> , 2017, 12, e0176075.	1.1	30
492	Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. <i>PLoS ONE</i> , 2017, 12, e0176782.	1.1	16
493	First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging. <i>Journal of Translational Science</i> , 2018, 5, .	0.2	11
494	Dosimetry Assessment of Injected 89Zr-Labeled Monoclonal Antibodies in Humans. <i>Radiation Research</i> , 2019, 191, 466.	0.7	14
495	Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab. <i>Oncotarget</i> , 2016, 7, 68111-68121.	0.8	16
496	Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. <i>Oncotarget</i> , 2014, 5, 6994-7012.	0.8	14
497	Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging. <i>Oncotarget</i> , 2015, 6, 4496-4504.	0.8	38
498	89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. <i>Oncotarget</i> , 2015, 6, 30384-30393.	0.8	106
499	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. <i>Oncotarget</i> , 2016, 7, 21247-21258.	0.8	86
500	Development of 89Zr-Ontuxizumab for <i>in vivo</i> TEM-1/Endosialin PET applications. <i>Oncotarget</i> , 2016, 7, 13082-13092.	0.8	13

#	ARTICLE	IF	CITATIONS
501	ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1. <i>Oncotarget</i> , 2016, 7, 25103-25112.	0.8	27
502	Antibody-Based Imaging of HER-2: Moving into the Clinic. <i>Current Molecular Medicine</i> , 2013, 13, 1523-1537.	0.6	14
503	⁸⁹ Zr Radiochemistry for Positron Emission Tomography. <i>Medicinal Chemistry</i> , 2011, 7, 389-394.	0.7	63
504	PET Tracers Based on Zirconium-89. <i>Current Radiopharmaceuticals</i> , 2011, 4, 131-139.	0.3	137
505	Radiotracers in Oncology. <i>Current Radiopharmaceuticals</i> , 2012, 5, 79-89.	0.3	3
506	The Bioconjugation and Radiosynthesis of ⁸⁹ Zr-DFO-labeled Antibodies. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	60
507	The emerging role of advanced neuroimaging techniques for brain metastases. <i>Chinese Clinical Oncology</i> , 2015, 4, 23.	0.4	13
508	Las dietas mediÁticas de los espa±oles. Estudio a travÁs de los usos del tiempo en 2009-2010. <i>Revista Internacional De Sociologia</i> , 2015, 73, e005.	0.0	2
509	Management of solitary and multiple brain metastases from breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 87-93.	0.1	18
510	Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10745.	1.8	19
511	Therapeutic antibodies “ natural and pathological barriers and strategies to overcome them. , 2022, 233, 108022.		15
512	Positron scattering from pyrazine. <i>Physical Review A</i> , 2021, 104, .	1.0	7
513	MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. <i>Science Translational Medicine</i> , 2021, 13, eabj4011.	5.8	82
514	Development of the First Aliphatic ¹⁸ F-Labeled Tetrazine Suitable for Pretargeted PET Imaging“Expanding the Bioorthogonal Tool Box. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15297-15312.	2.9	25
515	Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From the<i>AJR</i>Special Series on Imaging of Inflammation. <i>American Journal of Roentgenology</i> , 2022, 218, 940-952.	1.0	5
516	<i>In Vitro</i> Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells. <i>Oligonucleotides</i> , 0, , 121102072334007.	2.7	0
517	Radiotracers for Molecular Imaging of Breast Cancer. , 0, , .		0
518	Oesophago-Gastric Cancer. , 2012, , 221-244.		9

#	ARTICLE	IF	CITATIONS
519	Breast Cancer: Role of Planar, SPECT and PET in Imaging Bone Metastases. , 2012, , 661-689.		0
521	PET-CT Imaging in Breast Cancer Patients: New Tracers, Future Directions. Journal of Molecular Imaging & Dynamics, 2013, 02, .	0.2	0
522	Role of Molecular Imaging in the Era of Personalized Medicine: A Review. , 2014, , 43-58.		0
523	The Value of 11C-Methionine PET in the Differential Diagnosis Between Brain Tumor Recurrence and Radionecrosis. , 2014, , 895-910.		0
525	The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. BJR case Reports, 2014, 1, 20140065.	0.1	0
527	Role of HER2 in Gastric Cancers. , 2015, , 77-89.		0
529	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2016, , 1-25.		0
530	Chelators for Diagnostic Molecular Imaging with Radioisotopes of Copper, Gallium and Zirconium. 2-Oxoglutarate-Dependent Oxygenases, 2016, , 260-312.	0.8	2
531	Metastatic Breast Cancer. , 2016, , 451-474.		0
532	Physiologic and Molecular Basis of PET in Cancer Imaging. , 2017, , 399-427.		2
533	Imaging Biomarkers in Clinical Trials. , 2017, , 295-306.		0
534	Copper-Labeled Radiopharmaceuticals in Oncology. , 2017, , 195-211.		0
535	Nuclear Medicine in the Clinical Management (ROLL, SNB, and PET). , 2017, , 247-264.		0
536	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2017, , 613-637.		0
537	PET/MRI and Molecular Imaging in Breast Cancer. , 2018, , 83-98.		0
538	Pushing indium phosphide quantum dot emission deeper into the near infrared. , 2018, , .		0
539	Practical consensus recommendations on Her2 +ve breast cancer with solitary brain mets. South Asian Journal of Cancer, 2018, 07, 118-122.	0.2	2
540	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2019, , 463-494.		0

#	ARTICLE	IF	CITATIONS
541	Systemic control of cerebral metastases in a patient with HER2-positive metastatic breast cancer. Clinical case. Meditsinskiy Sovet, 2019, , 129-134.	0.1	0
542	Analyzing of Production Conditions of 89Zr in the Particle Accelerator. Cumhuriyet Science Journal, 2019, 40, 388-395.	0.1	0
543	Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides. Molecules, 2021, 26, 6482.	1.7	11
544	Radionuclide-Based Imaging of Breast Cancer: State of the Art. Cancers, 2021, 13, 5459.	1.7	18
546	Internal dosimetry modelling for 89Zr-labelled chimeric monoclonal antibody U36 based on real clinical results. AIP Conference Proceedings, 2020, , .	0.3	0
547	Cancer Imaging with Radiolabeled Monoclonal Antibodies. , 2020, , 739-760.		5
548	Integrating Systemic Therapy into the Management of Brain Metastases. , 2020, , 95-108.		0
549	A proof-of-concept methodology to validate the in situ visualization of residual disease using cancer-targeted molecular agents in fluorescence-guided surgery. , 2020, 11222, .		4
550	Nanoparticles for Cancer Diagnosis, Radionuclide Therapy and Theranostics. ACS Nano, 2021, 15, 16974-16981.	7.3	40
552	Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions. Molecular Imaging, 2011, 10, 177-86, 1-3.	0.7	58
554	Monoclonal antibodies in cancer therapy. Cancer Immunity, 2012, 12, 14.	3.2	206
555	ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. American Journal of Translational Research (discontinued), 2012, 4, 333-46.	0.0	38
556	EATRIS, a European initiative to boost translational biomedical research. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 166-74.	1.0	9
557	Leptomeningeal metastases in breast cancer. American Journal of Cancer Research, 2013, 3, 117-26.	1.4	36
559	Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Molecular Imaging, 2013, 12, 17-27.	0.7	41
561	Biodistribution Analyses of a Near-Infrared, Fluorescently Labeled, Bispecific Monoclonal Antibody Using Optical Imaging. Comparative Medicine, 2016, 66, 90-9.	0.4	7
562	Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 135-53.	1.0	15
563	Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis. Oncology, 2014, 28, 579, 584-5.	0.4	1

#	ARTICLE	IF	CITATIONS
565	HER2-targeted multimodal imaging of anaplastic thyroid cancer. American Journal of Cancer Research, 2019, 9, 2413-2427.	1.4	10
566	Development of zirconium-89 PET for imaging of alpha-klotho. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 95-105.	1.0	1
567	Adapting Imaging Protocols for PET-CT and PET-MRI for Immunotherapy Monitoring. Cancers, 2021, 13, 6019.	1.7	5
568	Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 12213.	1.8	12
569	Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models. Frontiers in Oncology, 2021, 11, 778728.	1.3	3
570	Al[¹⁸ F]-AEEA-HER2-BCH Affibody PET Imaging Accurately Depict HER2 Positive Lesions. SSRN Electronic Journal, 0, , .	0.4	0
571	Targeting brain metastases in breast cancer. Cancer Treatment Reviews, 2022, 103, 102324.	3.4	46
572	Targeted nuclear medicine. Seek and destroy. Russian Chemical Reviews, 2022, 91, .	2.5	19
573	Automated light-induced synthesis of ⁸⁹ Zr-radiolabeled antibodies for immuno-positron emission tomography. Scientific Reports, 2022, 12, 668.	1.6	5
574	Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases. Cancers, 2022, 14, 533.	1.7	4
575	Development ⁶⁸ Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patients. Nuclear Medicine Communications, 2022, 43, 458-467.	0.5	3
576	Nuclear medicine therapy of lung cancer, breast cancer and colorectal cancer. , 2022, , .		0
578	Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy. Cancers, 2022, 14, 965.	1.7	2
579	Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody-Drug Conjugates. Cancer Research, 2022, 82, 1858-1869.	0.4	4
580	Radiolabeled Antibodies for Cancer Imaging and Therapy. Cancers, 2022, 14, 1454.	1.7	28
581	First-time imaging of [⁸⁹ Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3593-3595.	3.3	11
582	Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens. Expert Review of Anticancer Therapy, 2022, 22, 505-522.	1.1	1
584	Non-invasive radionuclide imaging of trace metal trafficking in health and disease: “PET metallomics” RSC Chemical Biology, 2022, 3, 495-518.	2.0	5

#	ARTICLE	IF	CITATIONS
585	Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review. <i>Frontiers in Medicine</i> , 2022, 9, 881551.	1.2	11
587	⁸⁹ Zr-PET imaging to predict tumor uptake of ¹⁷⁷ Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma. <i>Scientific Reports</i> , 2022, 12, 6286.	1.6	3
591	⁸⁹ Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1523-1530.	2.8	15
592	Preliminary investigation of ⁴⁸ V-labeled VO(acac) ₂ for cancer imaging: An initial proof-of-concept study. <i>Applied Radiation and Isotopes</i> , 2022, 186, 110270.	0.7	4
593	Application of a Novel ⁶⁸ Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
594	Use of Radionuclide-Based Imaging Methods in Breast Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 561-573.	2.5	3
595	Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	13
596	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 82-92.	1.8	6
597	Novel applications of molecular imaging to guide breast cancer therapy. <i>Cancer Imaging</i> , 2022, 22, .	1.2	6
599	ImmunoPET: Antibody-Based PET Imaging in Solid Tumors. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	11
600	Antibody-based Radiopharmaceuticals as Theranostic Agents: An Overview. <i>Current Medicinal Chemistry</i> , 2022, 29, 5979-6005.	1.2	2
601	Therapeutic Response Monitoring with ⁸⁹ Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models. <i>Pharmaceutics</i> , 2022, 14, 1338.	2.0	3
602	Pilot study of a novel nanobody ⁶⁸ Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4394-4405.	3.3	7
603	Theranostics: Nuclear medicine for diagnosis and treatment of cancer. <i>Tenri Medical Bulletin</i> , 2022, 25, 1-13.	0.1	0
604	The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer. , 2022, 14, 4-15.		6
605	Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma. <i>Journal of Nuclear Medicine</i> , 2023, 64, 137-144.	2.8	5
606	⁸⁹ Zr-panitumumab Combined With ¹⁸ F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4425-4434.	3.2	5
607	Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	0

#	ARTICLE	IF	CITATIONS
608	Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada. <i>JAMA Network Open</i> , 2022, 5, e2225424.	2.8	7
609	Application of C-Terminal Clostridium Perfringens Enterotoxin in Treatment of Brain Metastasis from Breast Cancer. <i>Cancers</i> , 2022, 14, 4309.	1.7	5
610	A trimeric immunoglobulin G α C-binding domain outperforms recombinant protein G and protein L as a ligand for fragment antigen α C-binding purification. <i>Journal of Chromatography A</i> , 2022, 1681, 463464.	1.8	1
611	Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma. <i>Theranostics</i> , 2022, 12, 5615-5630.	4.6	8
612	Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
613	Novel Positron-Emitting Radiopharmaceuticals. , 2022, , 169-216.		0
614	HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking. <i>Theranostics</i> , 2022, 12, 5551-5563.	4.6	9
615	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2022, , 715-741.		0
616	Synthesis and comparative evaluation of ¹⁷⁷ Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
617	Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1457-1476.	1.3	1
618	Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy. , 2022, 141, 213125.		9
620	Theranostic applications. , 2022, , 197-213.		0
621	Protein and Peptide-Based Therapeutics for Cancer Imaging. , 2022, , 441-471.		0
622	Immuno-PET: Design options and clinical proof-of-concept. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
623	The production of the first functional antibody mimetic in higher plants: the chloroplast makes the DARPIn G3 for HER2 imaging in oncology. <i>Biological Research</i> , 2022, 55, .	1.5	3
624	Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis. <i>Med</i> , 2022, 3, 860-882.e15.	2.2	21
625	Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases. <i>ESMO Open</i> , 2022, 7, 100596.	2.0	2
626	Evaluation of ⁶⁸ Ga-Radiolabeled Peptides for HER2 PET Imaging. <i>Diagnostics</i> , 2022, 12, 2710.	1.3	1

#	ARTICLE	IF	CITATIONS
627	Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 5612.	1.7	1
628	Lasso peptide microcin J25 variant containing RGD motif as a PET probe for integrin $\alpha_v\beta_3$ in tumor imaging. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 180, 106339.	1.9	3
629	Synthesis and in vivo evaluation of [¹¹ C]tucatinib for HER2-targeted PET imaging. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 80, 129088.	1.0	2
630	⁶⁸ Ga-Labeled Trastuzumab Fragments for ImmunoPET Imaging of Human Epidermal Growth Factor Receptor 2 Expression in Solid Cancers. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 0, , .	0.7	1
631	CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin. <i>Biomaterials Research</i> , 2022, 26, .	3.2	12
632	ImmunoPET Directed to the Brain: A New Tool for Preclinical and Clinical Neuroscience. <i>Biomolecules</i> , 2023, 13, 164.	1.8	2
633	Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. <i>Breast</i> , 2023, 69, 441-450.	0.9	2
634	Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer ^{99m} Tc-HP-Ark2: a pilot study. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
635	Zirconium immune-complexes for PET molecular imaging: Current status and prospects. <i>Coordination Chemistry Reviews</i> , 2023, 479, 215005.	9.5	7
636	ImmunoPET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential. , 2023, , 1-34.		0
637	Justification of differential approach to management of patient biological waste in nuclear medicine departments. <i>RadiacionnaĀĀ Gigena</i> , 2023, 15, 34-44.	0.2	2
638	Radiochemical, Computational, and Spectroscopic Evaluation of High-Denticity Desferrioxamine Derivatives DFO2 and DFO2p toward an Ideal Zirconium-89 Chelate Platform. <i>Inorganic Chemistry</i> , 0, , .	1.9	1
639	The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years. <i>Current Medical Imaging</i> , 2023, 19, .	0.4	1
640	Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. <i>Cancer Treatment Reviews</i> , 2023, 115, 102527.	3.4	2
641	Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	25
642	Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	6
643	Positron Scattering from Pyrimidine. <i>Atoms</i> , 2023, 11, 55.	0.7	0
644	Technological advancements and future perspectives in breast cancer radiation therapy. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 407-419.	1.1	1

#	ARTICLE	IF	CITATIONS
649	Monitoring TGF β 2 signaling in irradiated tumors. <i>Methods in Cell Biology</i> , 2023, , 49-67.	0.5	0
662	PET receptor imaging in breast cancer. <i>Clinical and Translational Imaging</i> , 0, , .	1.1	0
684	Cancer Theranostics: Pharmaceutical View. , 0, , .		0